Adaptive Biotechnologies (ADPT) vs ImmunityBio (IBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmunityBio (IBRX) has outperformed Adaptive Biotechnologies (ADPT) over the past year, gaining 189.4% versus a gain of 50.1%. Over five years, ADPT leads with a -0.7% price change compared with -7.4% for IBRX. ImmunityBio is the larger company by market cap ($6.40 billion vs $4.52 billion), about 1.4 times the size.
Adaptive Biotechnologies converts more of its revenue into profit, with a net margin of -21.5% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | IBRX |
|---|---|---|
| Share price | $27.93 | $6.02 |
| Market cap | $4.52B | $6.40B |
| 1-day change | -0.43% | -8.37% |
| YTD return | +71.98% | +204.04% |
| 1-year return | +50.08% | +189.42% |
| 5-year return | -0.68% | -7.38% |
| EPS (TTM) | $-0.45 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $113.29M |
| Revenue growth (YoY) | +54.77% | +668.31% |
| Net income (latest FY) | $-59.50M | $-351.40M |
| Gross margin | 74.24% | 99.34% |
| Operating margin | -20.62% | -226.00% |
| Net margin | -21.48% | -310.18% |
| 52-week high | $32.21 | $12.43 |
| 52-week low | $12.00 | $1.95 |
| Distance from 52-week high | -13.29% | -51.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +21.23% | +136.71% |
| Average volume | 2.20M | 12.97M |
| Shares outstanding | 161.88M | 1.06B |
| Employees | 624 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed ADPT by 139.3 percentage points over the past year.
- Adaptive Biotechnologies is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +54.77%).
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
ADPT vs IBRX FAQ
Which is bigger, Adaptive Biotechnologies or ImmunityBio?
ImmunityBio (IBRX) is larger, with a market capitalization of $6.40B compared with $4.52B for Adaptive Biotechnologies (ADPT).
Which stock has performed better over the past year, ADPT or IBRX?
IBRX returned +189.42% over the past 12 months, compared with +50.08% for ADPT (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and ImmunityBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.